Inpatient Infections Pulse
Inpatient Infections Pulse
$599.00
We conducted a survey of 20 infectious diseases specialists to evaluate current drug usage for the treatment of selected severe/inpatient infections and gauge physician interest in new drugs.
Publisher: Biomedtracker
- Description
- Samples
We conducted a survey of 20 infectious diseases specialists to evaluate current drug usage for the treatment of selected severe/inpatient infections and gauge physician interest in new drugs.
Drug candidates discussed: Cubicin (daptomycin), Dalvance (dalbavancin), Orbactiv (oritavancin), Zyvox (linezolid), vancomycin, metronidazole, Dificid (fidaxomicin), Xifaxan (rifaximin); beta-lactam–beta-lactamase inhibitor combination drugs.
| Disease Group Covered: | Infectious disease |
Figure: Breakdown of Surveyed Oncologists
© Pharma Intelligence UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Zelapar 
Sign up to the